

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 71282

Title: Continuous intravenous infusion of Recombinant human endostatin (Rh-endostatin) using infusion pump plus chemotherapy in non-small cell lung cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06134818

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2021-09-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-18 05:41

Reviewer performed review: 2021-09-18 07:00

Review time: 1 Hour

Scientific quality	☐ Grade A: Excellent ☐ Grade B: Very good ☒ Grade C: Good ☐ Grade D: Fair ☐ Grade E: Do not publish
Language quality	☐ Grade A: Priority publishing ☒ Grade B: Minor language polishing ☐ Grade C: A great deal of language polishing ☐ Grade D: Rejection
Conclusion	☐ Accept (High priority) ☒ Accept (General priority) ☐ Minor revision ☐ Major revision ☐ Rejection
Re-review	☒ Yes ☐ No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [☐] Anonymous [☒] Onymous Conflicts-of-Interest: [☐] Yes [☒] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Although this draft did not establish a control group, but can be compared with other multicenter studies to demonstrate it's safety and efficacy.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 71282

Title: Continuous intravenous infusion of Recombinant human endostatin (Rh-endostatin) using infusion pump plus chemotherapy in non-small cell lung cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05833323

Position: Peer Reviewer

Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2021-09-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-20 00:35

Reviewer performed review: 2021-10-09 14:56

Review time: 19 Days and 14 Hours

Scientific quality	☐ Grade A: Excellent ☒ Grade B: Very good ☐ Grade C: Good ☐ Grade D: Fair ☐ Grade E: Do not publish
Language quality	☐ Grade A: Priority publishing ☒ Grade B: Minor language polishing ☐ Grade C: A great deal of language polishing ☐ Grade D: Rejection
Conclusion	☐ Accept (High priority) ☐ Accept (General priority) ☒ Minor revision ☐ Major revision ☐ Rejection
Re-review	☐ Yes ☒ No

**Peer-reviewer
statements**

Peer-Review: [☒] Anonymous [☐] Onymous
Conflicts-of-Interest: [☐] Yes [☒] No

SPECIFIC COMMENTS TO AUTHORS

This is an interesting study of the therapeutic outcomes and safety of continuous intravenous infusion of recombinant human endostatin in retreated advanced non-small cell lung cancer. In this study, the authors included patients received continuous intravenous infusion of Rh-endostatin using an infusion pump. The ORR, CBR, mPFS and incidences of adverse reactions were analyzed after treatment. The results showed that the favorable efficacy and safety of this treatment regimen were achieved in retreated advanced non-small cell lung cancer. The study is well designed and the results are very interesting. Minor comments: Please correct the minor language polishings, editing and updating the manuscript according to the journal's guideline.